Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your most recent bladder surgery (called TURBT) was done within the past 12 weeks, and results confirmed a specific type of high-risk bladder cancer that has not spread into the muscle wall
- Group A: You have high-risk, non-muscle-invasive bladder cancer (specific stages: HG Ta, T1, and/or CIS) and have either never received BCG treatment, or your last BCG treatment was more than 2 years ago with a full response before your cancer came back
- Group B: You have a specific type of non-muscle-invasive bladder cancer involving CIS (with or without other growths), and you are unable to have or are choosing not to have a particular bladder treatment called IVESIC therapy
- Group B: You are either BCG-naive (as described above), or you received BCG but not the full recommended amount and your cancer returned within 2 years of your last BCG dose
- Group B (HIV-positive patients only): Your HIV is well controlled with medication
Who may not be able to join:
- You have had, or currently have, bladder cancer that has spread into the muscle, surrounding tissue, or other parts of the body
- You have, or recently had (within the last 2 years), cancer affecting areas outside the bladder such as the urethra, ureter, or kidney (with some exceptions — confirm with trial site)
- You have another cancer that is still growing or required treatment within the last 3 years
- You had a heart attack within the past 6 months
- You received any cancer-fighting medication or experimental treatment within the past 4 weeks
- You have previously received a cancer vaccine
- You have a weakened immune system or are taking long-term steroid medication
- You have an autoimmune disease that needed medical treatment within the last 2 years
- You are unable to have a CT scan or MRI with contrast dye (confirm with trial site)
- Group A only: You currently have active tuberculosis
- Group A only: You have a known HIV infection
- Group B only: You are HIV-positive and have a history of Kaposi's sarcoma and/or a condition called Multicentric Castleman's Disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Australian sites
+61298122968
+61861511130
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Cohort A: Event-free Survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.